Nyxoah S.A. (NYXH) vs Atrium Therapeutics, Inc. (RNA)
A side-by-side comparison of Nyxoah S.A. and Atrium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NYXH
Nyxoah S.A.
$1.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RNA
Atrium Therapeutics, Inc.
$7.99HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NYXH vs RNA
growth of $100 · dividends reinvested · last 1yNYXH -70.0% (-70.0%/yr)RNA -46.0% (-46.0%/yr)RNA compounded faster over this window
NYXH RNA
NYXH vs RNA: by the numbers
- •NYXH is the larger company ($143M vs $137M market cap).
- •Both run net losses; RNA's is the smaller (-396.52% vs -435.70% net margin).
Metrics side by side
Valuation
| Metric | NYXH | RNA |
|---|---|---|
| P/S ratio | 5.46 | 5.82 |
| P/B ratio | 1.51 | 0.64 |
Profitability
| Metric | NYXH | RNA |
|---|---|---|
| Gross margin | 63.13% | 97.90% |
| Operating margin | -827.76% | -410.23% |
| Net margin | -435.70% | -396.52% |
| ROE | -120.33% | -43.42% |
| ROIC | -61.13% | -38.45% |
Growth (annualized)
| Metric | NYXH | RNA |
|---|---|---|
| Revenue CAGR (5Y) | 120.68% | N/A |
| Total return CAGR (5Y) | -45.84% | N/A |
Go deeper
Dig into the metrics
Nyxoah ROEAtrium Therapeutics ROENyxoah operating marginAtrium Therapeutics operating marginNyxoah revenue growthAtrium Therapeutics revenue growthNyxoah free cash flowAtrium Therapeutics free cash flow
Nyxoah & Atrium Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.